PubMed COVID-19 Clinical Care

Antiviral therapeutics to treat SARS-CoV-2 are needed to diminish the morbidity of the ongoing COVID-19 pandemic. A well-precedented drug target is the main viral protease (M^(Pro) ), which is targeted by an approved drug and by several

Since the start of the global COVID-19 pandemic, extensive quantities of face masks have been used and discarded. Most of these masks end up in landfills, causing a high environmental impact and no benefits. However, there are alternative ways to

Although over 13 billion COVID-19 vaccine doses have been administered globally, the issue of whether the optimal doses are being used has received little attention. To address this question we reviewed the reports of early-phase dose-finding trials

No abstract

No abstract

CONCLUSIONS: Although research on health services emphasizes the existence of several levels of local implementation of health policies, it offers little in the way of definition or characterization of these levels. The identification in this study

Three pilot studies (N(total) = 832) revealed that people held more positive attitudes toward targets wearing protective face masks. Therefore, we examined whether knowledge of this self-presentational benefit would increase people's intentions to

Long COVID, also known as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), has been defined as signs and symptoms which persist for 4 weeks or even lasting for 6 months after the initial infection. Although the prevalence of long COVID in children

The pediatric live-attenuated bovine/human parainfluenza virus type 3 (B/HPIV3)-vectored vaccine expressing the prefusion-stabilized SARS-CoV-2 spike (S) protein (B/HPIV3/S-2P) was previously evaluated in vitro and in hamsters. To improve its

CONCLUSIONS: People with long-term COVID experienced substantial decline in eGFR within one year from the infection date. The prevalence of proteinuria appeared to be high. Close monitoring of kidney function is prudent among patients with persistent